Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Autor(es):Mostrar menos -

Cabral-Marques, Otavio ; Moll, Guido ; Catar, Rusan ; Preuss, Beate ; Bankamp, Lukas ; Pecher, Ann-Christin ; Henes, Joerg ; Klein, Reinhild ; Kamalanathan, A. S. ; Akbarzadeh, Reza ; van Oostveen, Wieke ; Hohberger, Bettina ; Endres, Matthias ; Koolmoes, Bryan ; Levarht, Nivine ; Postma, Rudmer ; van Duinen, Vincent ; van Zonneveld, Anton Jan ; de Vries-Bouwstra, Jeska ; Fehres, Cynthia ; Tran, Florian ; Nery do Vale, Fernando Yuri ; da Silva Souza, Kamilla Batista ; Filgueiras, Igor Salerno ; Schimke, Lena F. ; Baiocchi, Gabriela Crispim ; de Miranda, Gustavo Cabral ; Mathias da Fonseca, Dennyson Leandro ; Freire, Paula Paccielli ; Hackel, Alexander M. ; Grasshoff, Hanna ; Stahle, Anja ; Mueller, Antje ; Dechend, Ralf ; Yu, Xinhua ; Petersen, Frank ; Sotzny, Franziska ; Sakmar, Thomas P. ; Ochs, Hans D. ; Schulze-Forster, Kai ; Heidecke, Harald ; Scheibenbogen, Carmen ; Shoenfeld, Yehuda ; Riemekasten, Gabriela

• Tipo de documento: Artigo Científico
• Fonte: AUTOIMMUNITY REVIEWS; v. 22, n. 5, p. 14-pg., 2023-03-14.

Resumo

G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial Interna-tional Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lubeck, Germany, 15-16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy in-dividuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, repre-senting a new area for the development of novel therapeutic interventions. (AU)

• Processo FAPESP: 18/18886-9 - Análise sistêmica e integrativa da resposta imune às infecções virais por Zika e Dengue
• Beneficiário: Otávio Cabral Marques
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 20/16246-2 - Caracterização holística do mecanismo de exaustão dos linfócitos T em pacientes com Zika
• Beneficiário: Dennyson Leandro Mathias da Fonseca
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 20/01688-0 - Análise sistêmica e integrativa da resposta imune às infecções virais por Zika e Dengue
• Beneficiário: Otávio Cabral Marques
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores
• Processo FAPESP: 20/07069-0 - Análise sistêmica e integrativa dos mecanismos de exaustão dos linfócitos T de pacientes com COVID-19
• Beneficiário: Otávio Cabral Marques
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 20/07972-1 - Análise sistêmica e integrativa dos mecanismos de exaustão dos linfócitos T de pacientes com COVID-19
• Beneficiário: Gabriela Crispim Baiocchi
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 20/05146-7 - Desenvolvimento de vacina anti-SARS-CoV-2 utilizando VLPs
• Beneficiário: Gustavo Cabral de Miranda
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 19/14526-0 - Desenvolvimento de vacinas contra Streptococcus pyogenes e Chikungunya utilizando VLPs
• Beneficiário: Gustavo Cabral de Miranda
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores